4/30/2013

Impax Laboratories will regain the rights to develop and market IPX066, an experimental Parkinson's disease drug, in certain countries after agreeing to end a collaboration deal with GlaxoSmithKline. The firms cited regulatory and commercialization delays in countries where GSK holds the right to sell the drug, known as Rytary in the U.S., as the reason for the deal's termination.

Full Story:
Reuters

Related Summaries